Bcl-2 and Lung Cancer Survival
Author Information
Author(s): Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, Meert A-P, Steels E, Vallot F, Verdebout J-M, Lafitte J-J, Sculier J-P
Primary Institution: Institut Jules Bordet
Hypothesis
Does Bcl-2 overexpression serve as a prognostic factor for survival in lung cancer patients?
Conclusion
Bcl-2 overexpression is associated with better survival outcomes in patients with non-small cell lung cancer.
Supporting Evidence
- 11 of the 28 studies identified Bcl-2 expression as a good prognostic factor for survival.
- Overall, Bcl-2 protein was expressed in 39% of the lung tumors studied.
- The aggregated survival data showed a good survival prognosis where there was Bcl-2 positivity (HR=0.72).
- Statistically significant HR of 0.70 was found for stages I and II NSCLC.
- Surgically treated NSCLC showed a significant HR of 0.50.
Takeaway
This study found that patients with a certain protein called Bcl-2 in their lung tumors tend to live longer than those without it.
Methodology
A systematic review and meta-analysis of 28 trials assessing the prognostic value of Bcl-2 expression in lung cancer.
Potential Biases
There is a risk of bias due to the exclusion of unpublished studies and the reliance on published data, which may favor positive results.
Limitations
The study is limited by potential publication bias and the heterogeneity of patient populations across trials.
Participant Demographics
The studies included a total of 3370 patients with lung cancer, primarily focusing on non-small cell lung cancer.
Statistical Information
P-Value
0.0015
Confidence Interval
95% CI 0.64–0.82
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website